```
FILE 'HOME' ENTERED AT 09:11:32 ON 03 NOV 2006

=> file reg
COST IN U.S. DOLLARS                                   SINCE FILE      TOTAL
                                                            ENTRY    SESSION
FULL ESTIMATED COST                                          0.21       0.21

FILE 'REGISTRY' ENTERED AT 09:12:06 ON 03 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    2 NOV 2006  HIGHEST RN 912331-22-7
DICTIONARY FILE UPDATES:   2 NOV 2006  HIGHEST RN 912331-22-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\brimonidine1.str

L1       STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1               STR
```



```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 fam sam
SAMPLE SEARCH INITIATED 09:12:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED        0 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:                0 TO          0
PROJECTED ANSWERS:                   0 TO          0
```

```
L2            0 SEA FAM SAM L1

=> s l1 fam full
FULL SEARCH INITIATED 09:12:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      20 TO ITERATE

100.0% PROCESSED       20 ITERATIONS                          0 ANSWERS
SEARCH TIME: 00.00.01

L3            0 SEA FAM FUL L1

=> file caplus
COST IN U.S. DOLLARS                                 SINCE FILE      TOTAL
                                                          ENTRY    SESSION
FULL ESTIMATED COST                                       65.69      65.90

FILE 'CAPLUS' ENTERED AT 09:12:58 ON 03 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 3 Nov 2006  VOL 145 ISS 19
FILE LAST UPDATED: 1 Nov 2006  (20061101/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 59803-98-4
   REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.





L5          804 L4


=> d scan

L5     804 ANSWERS   CAPLUS  COPYRIGHT 2006 ACS on STN
CC     63-5 (Pharmaceuticals)
       Section cross-reference(s): 1
TI     Polycarboxylic acid nanoparticles for ophthalmic drug delivery: An ex vivo
       evaluation with human cornea
ST     polycarboxylate nanoparticle ophthalmic drug delivery human; brimonidine
       human cornea polyacrylate polyitaconate nanoparticle
```

```
IT   Eye
        (cornea, epithelium; polycarboxylic acid nanoparticles for ophthalmic
        drug delivery and ex vivo evaluation with human cornea)
IT   Epithelium
        (corneal; polycarboxylic acid nanoparticles for ophthalmic drug
        delivery and ex vivo evaluation with human cornea)
IT   Drug delivery systems
        (nanoparticles; polycarboxylic acid nanoparticles for ophthalmic drug
        delivery and ex vivo evaluation with human cornea)
IT   Drug bioavailability
     Human
     Particle size
     Particle size distribution
     Stability
        (polycarboxylic acid nanoparticles for ophthalmic drug delivery and ex
        vivo evaluation with human cornea)
IT   Carboxylic acids, biological studies
     RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL
     (Biological study)
        (polycarboxylic; polycarboxylic acid nanoparticles for ophthalmic drug
        delivery and ex vivo evaluation with human cornea)
IT   59803-98-4, Brimonidine
     RL: PKT (Pharmacokinetics); BIOL (Biological study)
        (polycarboxylic acid nanoparticles for ophthalmic drug delivery and ex
        vivo evaluation with human cornea)
IT   9003-01-4, Polyacrylic acid   25119-64-6, Polyitaconic acid
     RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
     (Uses)
        (polycarboxylic acid nanoparticles for ophthalmic drug delivery and ex
        vivo evaluation with human cornea)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L5    804 ANSWERS   CAPLUS  COPYRIGHT 2006 ACS on STN
IC   ICM  A61K031-58
     ICS  A61K045-06; A61P027-02; A61P027-06
CC   2-4 (Mammalian Hormones)
TI   Methods and compositions for treating ophthalmic disorders with
     epoxy-steroidal aldosterone receptor antagonists
ST   epoxysteroid aldosterone receptor antagonist ophthalmic disorders
     treatment antiglaucoma
IT   Epoxy group
        (9,11-epoxy moiety-containing steroids; methods and compns. for treating
        ophthalmic disorders with epoxy-steroidal aldosterone receptor
        antagonists)
IT   Prostaglandins
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (A; methods and compns. for treating ophthalmic disorders with
        epoxy-steroidal aldosterone receptor antagonists in combination with
        cytoskeletal disrupting agents and/or prostaglandin compds.)
IT   Adenosine receptors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (A3, antagonists; methods and compns. for treating ophthalmic disorders
        with epoxy-steroidal aldosterone receptor antagonists in combination
        with antiglaucoma agents)
IT   Prostaglandins
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (B; methods and compns. for treating ophthalmic disorders with
        epoxy-steroidal aldosterone receptor antagonists in combination with
        cytoskeletal disrupting agents and/or prostaglandin compds.)
IT   Dopamine agonists
        (D1; methods and compns. for treating ophthalmic disorders with
```

epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT Prostaglandins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(E; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)

IT Prostaglandins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(F; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)

IT Muscarinic agonists
(M3; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT Muscarinic agonists
(M1; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT Prostaglandins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PGD; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with cytoskeletal disrupting agents and/or prostaglandin compds.)

IT Somatostatin receptors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SSTR4, agonists; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT Tumor necrosis factors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(agonists; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT Corticosteroid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT Eye
(anterior chamber, aqueous humor inflow/outflow; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)

IT Eye
(aqueous humor, controlled inflow/outflow; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)

IT Anion exchangers
(chloride, inhibitors; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists in combination with antiglaucoma agents)

IT Eye, disease
(diabetic retinopathy; methods and compns. for treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists)

IT Steroids, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epoxy-; methods and compns. for treating ophthalmic disorders with

```
        epoxy-steroidal aldosterone receptor antagonists)
IT   Mineralocorticoid receptors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (epoxysteroidal antagonist; methods and compns. for treating ophthalmic
        disorders with epoxy-steroidal aldosterone receptor antagonists)
IT   Transport proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (hydrogen ion-sodium exchanger, inhibitors; methods and compns. for
        treating ophthalmic disorders with epoxy-steroidal aldosterone receptor
        antagonists in combination with antiglaucoma agents)
IT   Eye
        (intraocular fluid; methods and compns. for treating ophthalmic
        disorders with epoxy-steroidal aldosterone receptor antagonists)
IT   Glaucoma (disease)
        (low-tension; methods and compns. for treating ophthalmic disorders
        with epoxy-steroidal aldosterone receptor antagonists)
IT   Eye, disease
        (macula, senile degeneration; methods and compns. for treating
        ophthalmic disorders with epoxy-steroidal aldosterone receptor
        antagonists)
IT   Eye, disease
        (macular edema; methods and compns. for treating ophthalmic disorders
        with epoxy-steroidal aldosterone receptor antagonists)
IT   Glaucoma (disease)
     Human
        (methods and compns. for treating ophthalmic disorders with
        epoxy-steroidal aldosterone receptor antagonists)
IT   Adrenoceptor agonists
     Antiglaucoma agents
     Cholinergic agonists
     Cholinergic antagonists
     Muscarinic agonists
     α-Adrenoceptor antagonists
     β-Adrenoceptor antagonists
     β2-Adrenoceptor antagonists
        (methods and compns. for treating ophthalmic disorders with
        epoxy-steroidal aldosterone receptor antagonists in combination with
        antiglaucoma agents)
IT   Cannabinoids
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (methods and compns. for treating ophthalmic disorders with
        epoxy-steroidal aldosterone receptor antagonists in combination with
        antiglaucoma agents)
IT   Cytoskeleton
        (methods and compns. for treating ophthalmic disorders with
        epoxy-steroidal aldosterone receptor antagonists in combination with
        cytoskeletal disrupting agents and/or prostaglandin compds.)
IT   Prostaglandins
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (methods and compns. for treating ophthalmic disorders with
        epoxy-steroidal aldosterone receptor antagonists in combination with
        cytoskeletal disrupting agents and/or prostaglandin compds.)
IT   Prostaglandins
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (prodrugs; methods and compns. for treating ophthalmic disorders with
        epoxy-steroidal aldosterone receptor antagonists in combination with
        cytoskeletal disrupting agents and/or prostaglandin compds.)
IT   Prostaglandins
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (prostanoids; methods and compns. for treating ophthalmic disorders
      with epoxy-steroidal aldosterone receptor antagonists in combination
      with cytoskeletal disrupting agents and/or prostaglandin compds.)
IT    Drug delivery systems
      (solns., ophthalmic; methods and compns. for treating ophthalmic
      disorders with epoxy-steroidal aldosterone receptor antagonists in
      combination with antiglaucoma agents)
IT    9001-03-0, Carbonic anhydrase
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
      (I, II and IV inhibitors; methods and compns. for treating ophthalmic
      disorders with epoxy-steroidal aldosterone receptor antagonists in
      combination with antiglaucoma agents)
IT    551-11-1, PGF2α
      RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
      (Biological study); USES (Uses)
      (agonists; methods and compns. for treating ophthalmic disorders with
      epoxy-steroidal aldosterone receptor antagonists in combination with
      cytoskeletal disrupting agents and/or prostaglandin compds.)
IT    11128-99-7, Angiotensin II
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
      (antagonists; methods and compns. for treating ophthalmic disorders
      with epoxy-steroidal aldosterone receptor antagonists in combination
      with antiglaucoma agents)
IT    26921-17-5, Timolol maleate
      RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
      (Biological study); USES (Uses)
      (in solution with dorzolamide hydrochloride; methods and compns. for
      treating ophthalmic disorders with epoxy-steroidal aldosterone receptor
      antagonists in combination with antiglaucoma agents)
IT    141436-78-4, Protein kinase C   182372-13-0, Rho kinase
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
      (inhibitors; methods and compns. for treating ophthalmic disorders with
      epoxy-steroidal aldosterone receptor antagonists in combination with
      antiglaucoma agents)
IT    7440-09-7, Potassium, biological studies   7440-23-5, Sodium, biological
      studies
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
      (methods and compns. for modulating intraocular ionic levels with
      epoxy-steroidal aldosterone receptor antagonists for treating
      ophthalmic disorders)
IT    95716-76-0   95716-78-2   95716-94-2   95716-95-3   95716-96-4
      95716-97-5   95716-98-6   95716-99-7   95717-02-5   107724-20-9
      380606-04-2
      RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
      (Biological study); USES (Uses)
      (methods and compns. for treating ophthalmic disorders with
      epoxy-steroidal aldosterone receptor antagonists)
IT    51-43-4, Epinephrine   51-48-9, L-Thyroxine, biological studies   51-83-2,
      Carbachol   54-71-7, Pilocarpine hydrochloride   59-66-5, Acetazolamide
      92-13-7, Pilocarpine   120-97-8, Dichlorophenamide   554-57-4,
      Methazolamide   4205-90-7, Clonidine   26839-75-8, Timolol   27912-14-7,
      Betagan   51781-21-6, Carteolol hydrochloride 59803-98-4,
      Brimonidine   63659-18-7, Betaxolol   63659-19-8, Betaxolol hydrochloride
      66711-21-5, Apraclonidine   94421-68-8, Anandamide   120279-96-1,
      Dorzolamide   130693-82-2, Dorzolamide hydrochloride   138890-62-7,
      Brinzolamide   150937-43-2   151499-39-7, Bafilomycin
      RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
      (Biological study); USES (Uses)
      (methods and compns. for treating ophthalmic disorders with
      epoxy-steroidal aldosterone receptor antagonists in combination with
      antiglaucoma agents)
IT    120373-36-6, Unoprostone   130209-82-4, Latanoprost   155206-00-1, Lumigan
      157283-68-6, Travoprost
      RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
      (Biological study); USES (Uses)
```

```
        (methods and compns. for treating ophthalmic disorders with
        epoxy-steroidal aldosterone receptor antagonists in combination with
        cytoskeletal disrupting agents and/or prostaglandin compds.)
IT    9000-83-3, ATPase
      RL: BSU (Biological study, unclassified); BIOL (Biological study)
         (vacuolar proton, inhibitors; methods and compns. for treating
         ophthalmic disorders with epoxy-steroidal aldosterone receptor
         antagonists in combination with antiglaucoma agents)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d his

     (FILE 'HOME' ENTERED AT 09:11:32 ON 03 NOV 2006)

     FILE 'REGISTRY' ENTERED AT 09:12:06 ON 03 NOV 2006
L1              STRUCTURE UPLOADED
L2            0 S L1 FAM SAM
L3            0 S L1 FAM FULL

     FILE 'CAPLUS' ENTERED AT 09:12:58 ON 03 NOV 2006
                S 59803-98-4/REG#

     FILE 'REGISTRY' ENTERED AT 09:13:22 ON 03 NOV 2006
L4            1 S 59803-98-4/RN

     FILE 'CAPLUS' ENTERED AT 09:13:22 ON 03 NOV 2006
L5          804 S L4

=> s parkinson's(w)disease
MISMATCHED QUOTE 'PARKINSON'S'
Quotation marks (or apostrophes) must be used in pairs,
one before and one after the expression you are setting
off or masking.

=> s parkinsons(w)disease
          1138 PARKINSONS
        899421 DISEASE
        244431 DISEASES
       1009820 DISEASE
                 (DISEASE OR DISEASES)
L6         967 PARKINSONS(W)DISEASE

=> s l4 and l6
           804 L4
L7           0 L4 AND L6

=> s alzheimers(w)disease
          2974 ALZHEIMERS
        899421 DISEASE
        244431 DISEASES
       1009820 DISEASE
                 (DISEASE OR DISEASES)
L8        2294 ALZHEIMERS(W)DISEASE

=> s l4 and l8
           804 L4
L9           0 L4 AND L8

=> s alpha(w)2(w)receptor(w)agonist
       1641980 ALPHA
          2486 ALPHAS
       1642085 ALPHA
                 (ALPHA OR ALPHAS)
        8930375 2
         673226 RECEPTOR
         617539 RECEPTORS
         801237 RECEPTOR
                  (RECEPTOR OR RECEPTORS)
         108778 AGONIST
          81524 AGONISTS
         148707 AGONIST
                  (AGONIST OR AGONISTS)
L10         156 ALPHA(W)2(W)RECEPTOR(W)AGONIST

=> s l10 and l6
L11           0 L10 AND L6

=> s l10 and l8
L12           0 L10 AND L8

=>
```

```
L5    ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN    59803-98-4  REGISTRY
ED    Entered STN:  16 Nov 1984
CN    6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)- (9CI)  (CA
      INDEX NAME)
OTHER NAMES:
CN    5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline
CN    AGN 190342
CN    Brimonidine
CN    Bromoxidine
CN    UK 14304
CN    UK 14304-18
DR    109826-55-3
MF    C11 H10 Br N5
CI    COM
LC    STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
        BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU,
        DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSDRUGNEWS, IMSPATENTS,
        IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS, RTECS*,
        SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
          (*File contains numerically searchable property data)
      Other Sources:   WHO
```



```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             804 REFERENCES IN FILE CA (1907 TO DATE)
              10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
             804 REFERENCES IN FILE CAPLUS (1907 TO DATE)
```